Photo of Jane J. Kim,  PhD

Jane J. Kim, PhD

Harvard T.H. Chan School Of Public Health

Harvard T.H. Chan School Of Public Health

Jane J. Kim, PhD

Harvard T.H. Chan School Of Public Health

EDUCATIONAL TITLES

  • Associate Professor, Health Policy and Management, Harvard T.H. Chan School Of Public Health

DF/HCC PROGRAM AFFILIATION

Publications

Powered by Harvard Catalyst
  • Haas JS, Sprague BL, Klabunde CN, Tosteson AN, Chen JS, Bitton A, Beaber EF, Onega T, Kim JJ, MacLean CD, Harris K, Yamartino P, Howe K, Pearson L, Feldman S, Brawarsky P, Schapira MM, . Provider Attitudes and Screening Practices Following Changes in Breast and Cervical Cancer Screening Guidelines. J Gen Intern Med 2015. PubMed
  • Beaber EF, Kim JJ, Schapira MM, Tosteson AN, Zauber AG, Geiger AM, Kamineni A, Weaver DL, Tiro JA, . Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening. Journal of the National Cancer Institute 2015; 107:djv120. PubMed
  • Campos NG, Castle PE, Wright TC, Kim JJ. Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage. Int J Cancer 2015. PubMed
  • Levin CE, Sharma M, Olson Z, Verguet S, Shi JF, Wang SM, Qiao YL, Jamison DT, Kim JJ. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China. Vaccine 2015. PubMed
  • Campos NG, Maza M, Alfaro K, Gage JC, Castle PE, Felix JC, Cremer ML, Kim JJ. The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador. Int J Cancer 2015. PubMed
  • Campos NG, Burger EA, Sy S, Sharma M, Schiffman M, Rodriguez AC, Hildesheim A, Herrero R, Kim JJ. An updated natural history model of cervical cancer: derivation of model parameters. Am J Epidemiol 2014; 180:545-55. PubMed
  • Kim JJ. Practice-based evidence for primary HPV testing in the United States. Journal of the National Cancer Institute 2014. PubMed
  • Burger EA, Sy S, Nygård M, Kristiansen IS, Kim JJ. Too Late to Vaccinate? The Incremental Benefits and Cost-effectiveness of a Delayed Catch-up Program Using the 4-Valent Human Papillomavirus Vaccine in Norway. J Infect Dis 2014. PubMed
  • Burger EA, Kim JJ. The value of improving failures within a cervical cancer screening program: An example from Norway. Int J Cancer 2014. PubMed
  • Burger EA, Sy S, Nygård M, Kristiansen IS, Kim JJ. Prevention of HPV-Related Cancers in Norway: Cost-Effectiveness of Expanding the HPV Vaccination Program to Include Pre-Adolescent Boys. PLoS ONE 2014; 9:e89974. PubMed
  • Kiatpongsan S, Kim JJ. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries. PLoS ONE 2014; 9:e106836. PubMed
  • Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim JJ. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. Vaccine 2013; 31 Suppl 7:H71-9. PubMed
  • Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S, . Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013; 31 Suppl 7:H1-31. PubMed
  • Seoud M, Vaccarella S, El-Kak F, Sancho-Garnier H, Jumaan AO, Kim JJ, Garland SM, Stern PL, LaMontagne DS, Albero G, Bosch FX. Extended Middle East and North Africa: summary recommendations for the prevention of human papillomavirus infections and related cancers including cervical cancer. Vaccine 2013; 31 Suppl 6:G78-9. PubMed
  • Kim JJ, Sharma M, O'Shea M, Sweet S, Diaz M, Sancho-Garnier H, Seoud M. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA). Vaccine 2013; 31 Suppl 6:G65-77. PubMed
  • Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S, . Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013; 31 Suppl 6:G1-31. PubMed
  • Denny LA, Sankaranarayanan R, De Vuyst H, Kim JJ, Adefuye PO, Alemany L, Adewole IF, Awolude OA, Parham G, de Sanjosé S, Bosch FX. Recommendations for cervical cancer prevention in sub-saharan Africa. Vaccine 2013; 31 Suppl 5:F73-4. PubMed
  • Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S, . Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013; 31 Suppl 5:F1-31. PubMed
  • Kim JJ, Campos NG, O'Shea M, Diaz M, Mutyaba I. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa. Vaccine 2013; 31 Suppl 5:F60-72. PubMed
  • Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S, . Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013; 31 Suppl 8:I1-31. PubMed
  • Kim JJ, Sharma M, Ortendahl J. Optimal interval for routine cytologic screening in the United States. JAMA Intern Med 2013; 173:241-2. PubMed
  • Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine 2012; 30 Suppl 5:F157-67. PubMed
  • Sharma M, Bruni L, Diaz M, Castellsagué X, Sanjosé SD, Bosch FX, Kim JJ. Using HPV prevalence to predict cervical cancer incidence. Int J Cancer 2012. PubMed
  • Kiatpongsan S, Campos NG, Kim JJ. Potential benefits of second-generation human papillomavirus vaccines. PLoS ONE 2012; 7:e48426. PubMed
  • Kim JJ,Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359:821-32. PubMed
Hide